Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Carol A. Pollock"'
Publikováno v:
Current Opinion in Nephrology & Hypertension. 31:129-134
PURPOSE OF REVIEW Diabetic kidney disease (DKD) is a significant health concern. Innovative strategies to prevent or limit the progression of DKD are urgently needed due to the limitation of existing treatments. KCa3.1, a potassium channel, is involv
Autor:
Nguyen Huu Man, Chaicharn Deerochanawong, Chin Meng Khoo, Ketut Suastika, Kun-Ho Yoon, Ambrish Mithal, Carol A. Pollock, Andrea O.Y. Luk, Linong Ji, Bien J. Matawaran, Siew Pheng Chan, Wayne Huey-Herng Sheu, Juliana C.N. Chan
Publikováno v:
Diabetes, Obesity & Metabolism
Early onset of type 2 diabetes and a high prevalence of co‐morbidities predispose the Asian population to a high risk for, and rapid progression of, diabetic kidney disease (DKD). Apart from renin‐angiotensin system inhibitors, sodium‐glucose c
Autor:
Rajiv Agarwal, Richard Oh, Kenneth W. Mahaffey, George Capuano, Christopher P. Cannon, David M. Charytan, Bruce Neal, George Bakris, Adeera Levin, Dick de Zeeuw, Megumi Oshima, Meg Jardine, Carol A. Pollock, David C. Wheeler, Hiddo J.L. Heerspink, Tom Greene, Hong Zhang, Robert Edwards, Norman Rosenthal, Vlado Perkovic, Bernard Zinman
Publikováno v:
Clin J Am Soc Nephrol
BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidne
Publikováno v:
Nutrients; Volume 14; Issue 4; Pages: 785
Diabetic kidney disease (DKD) progresses at different rates among patients with type 2 diabetes mellitus (T2D). Early identification of patients with a higher risk of DKD progression is essential to improve prognosis. Epigenetic modifications, partic
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 9641, p 9641 (2021)
International Journal of Molecular Sciences, Vol 22, Iss 9641, p 9641 (2021)
Diabetic kidney disease (DKD) is a progressive disorder, which is increasing globally in prevalence due to the increased incidence of obesity and diabetes mellitus. Despite optimal clinical management, a significant number of patients with diabetes d
Autor:
David C. Wheeler, Peter Rossing, Bergur V. Stefánsson, Hiddo J.L. Heerspink, Carol A. Pollock, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström
Publikováno v:
Pollock, C, Stefánsson, B, Reyner, D, Rossing, P, Sjöström, C D, Wheeler, D C, Langkilde, A M & Heerspink, H J L 2019, ' Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT) : a randomised, double-blind, placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 6, pp. 429-441 . https://doi.org/10.1016/S2213-8587(19)30086-5
Lancet Diabetes & Endocrinology, 7(6), 429-441. ELSEVIER SCIENCE INC
Lancet Diabetes & Endocrinology, 7(6), 429-441. ELSEVIER SCIENCE INC
Background: In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co-tran
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 1525, p 1525 (2021)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Mitochondria are critical organelles that play a key role in cellular metabolism, survival, and homeostasis. Mitochondrial dysfunction has been implicated in the pathogenesis of diabetic kidney disease. The function of mitochondria is critically regu
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Receptor-interacting protein kinase-3 (RIPK3) is a multifunctional regulator of cell death and inflammation. RIPK3 controls cellular signalling through the formation of the domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, w
Autor:
Adeera Levin, Rose Qiu, Dick de Zeeuw, David M. Charytan, David C. Wheeler, Christopher P. Cannon, Bernard Zinman, Meg Jardine, Harpreet S. Bajaj, Gian Luca Di Tanna, Rajiv Agarwal, Kenneth W. Mahaffey, Megumi Oshima, Vlado Perkovic, Hiddo J.L. Heerspink, Carol A. Pollock, Bruce Neal, Hong Zhang, Norman Rosenthal, George L. Bakris, Zien Zhou, Scott Bull, Tao Sun, Tom Greene
Publikováno v:
Journal of the American Society of Nephrology, 31(5), 1128-1139. AMER SOC NEPHROLOGY
J Am Soc Nephrol
J Am Soc Nephrol
BACKGROUND: Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR). METHODS: CREDENCE randoml
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75cc49e0de93f3c4191f2b4825756550
https://research.rug.nl/en/publications/05e58d3f-d008-43f7-9d77-9bc4dfb474fe
https://research.rug.nl/en/publications/05e58d3f-d008-43f7-9d77-9bc4dfb474fe
Autor:
Min Jun, Alan Cass, Germaine Wong, Louisa Sukkar, David Peiris, Roberto Pecoits-Filho, Celine Foote, John Knight, Martin Gallagher, Brendon L. Neuen, Carol A. Pollock, Kris Rogers, Tamara Young, David R. Sullivan, Amy Kang, Carinna Hockham, Meg Jardine
Publikováno v:
Diabetes Care
OBJECTIVE To determine the incidence of and factors associated with an estimated glomerular filtration rate (eGFR) RESEARCH DESIGN AND METHODS We identified people with diabetes in the EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (EXT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61889df3f9055a480cde587563f48081
https://europepmc.org/articles/PMC7809711/
https://europepmc.org/articles/PMC7809711/